Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207500 | 0.89 | TSHR (0.42) | MAPTCYP3A4CA1CA2CA12 | |
| SCHEMBL445487 | 0.77 | CA1 (0.64) | MAPTRAB9ACA1CA2CA12 | |
| SCHEMBL7490983 | 0.76 | CA12 (0.65) | MAPTRAB9ACA1CA2CA12 | |
| SCHEMBL18866772 | 0.76 | HCRTR2 (0.41) | GAACA1CA2CA12CA9 | |
| SCHEMBL22629143 | 0.76 | ALDH1A1 (0.42) | RAB9ALMNAGAACA1CA2 | |
| SCHEMBL23434553 | 0.76 | CCNT1 (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL15856116 | 0.75 | CA12 (0.66) | MAPTRAB9ACA1CA2CA12 | |
| SCHEMBL22615372 | 0.74 | MAPT (0.47) | MAPTRAB9ACYP3A4LMNAGAA | |
| SCHEMBL19744392 | 0.74 | RAB9A (0.41) | MAPTRAB9ALMNANPC1SMN1; SMN2 | |
| SCHEMBL6608601 | 0.73 | MGLL (0.49) | MAPTRAB9ALMNAGAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | KCNJ2, KCNN2, KCNH2 | MAPT 4212/4885RAB9A 3574/4885CYP3A4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.